Updates

February 26, 2021February 24, 2021
Why It’s Important to Have People Who Validate Your Pain

“I love you, dud!” I hollered after my 3-year-old son as he blissfully skipped back to play with his brothers. (It’s unfortunate that while I ... Read more
February 24, 2021February 22, 2021
Beauty for Ashes: Finding the Good in the Suffering

Have you ever felt like you drew the short end of the stick in life? Do other people seem to have more reasons to be ... Read more
February 24, 2021February 23, 2021
How Medical Marijuana Has Reduced My AS Pain

Medicinal marijuana has been a true lifesaver for me as someone with ankylosing spondylitis (AS). I have so much gratitude and appreciation for this ... Read more
February 22, 2021February 22, 2021
IL-17A Inhibitors Appear Effective in Treating AS, But Safety Needs Further Study

Medications that block the activity of the pro-inflammatory molecule interleukin-17A (IL-17A) can ease symptoms of ankylosing spondylitis (AS), but further research is needed to ... Read more
February 18, 2021February 18, 2021
Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients

People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

March 7, 2018March 7, 2018

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

News

Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never been ... Read more

Updates

Why It’s Important to Have People Who Validate Your Pain

Beauty for Ashes: Finding the Good in the Suffering

How Medical Marijuana Has Reduced My AS Pain

IL-17A Inhibitors Appear Effective in Treating AS, But Safety Needs Further Study

Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients

Subscribe to our mailing list

A Chat With Luke Magda About AS and the Carnivore Diet

FDA Gives Thumb’s Up for Phase 2 Trial of Izokibep in AS Patients

Here Are the Dietary Changes That Reduced My AS Symptoms

Pandemic Won’t Stop Rare Disease Day on Feb. 28

High Pain Sensitivity in Patients Linked to Worse Clinical Outcomes

A Visitor’s Guide to the Montana Radon Health Mines, Part 2

NORD’s 6th ‘State Report Card’ Notes Progress, Raises Concerns

Rinvoq Approved in EU for Two Types of Active Arthritis

After Diagnosis, I Discovered That Knowledge Boosts My Confidence

COVID-19 Vaccines Pose Little Risk to Rare Disease Patients, FDA, CDC Say

Quality of Life, Work Appear to Improve for Patients Taking Humira in China

NORD’s Caregiver Respite Program Continues Through Pandemic

My Experience With Radon Mine Therapy for Ankylosing Spondylitis, Part 1

FDA Approves Generic Version of Celebrex

After Diagnosis, Treatment Options Can Boost Hope

NORD Seeks Speakers for 2021 Virtual ‘Living Rare, Living Stronger’ Forum

Targeting Calcium‐sensing Receptor May Help Slow Disease Progression

Cosentyx Shown to Reduce Fatigue for Up to 3 Years in Active AS Patients

Sex Differences Found in nr-axSpA Disease Severity, Treatment Response

Rinvoq Recommended for EU Approval to Treat Active AS

When ‘Imagined’ Pain Becomes a Real Diagnosis

Have a DIY Spa Day for Your Aches and Pains

Humira Biosimilar AVT02 Accepted for Regulatory Review in US, Europe

What My Nightly Struggle With Invisible Illness Looked Like

NORD Push for Rare Disease Advisory Councils Focus of Dec. 16 Public Meeting

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows